Valencell recognized as one of “the best in digital health” for its biometric sensor systems and cuff-less blood pressure technology for wearables & hearables
NEW YORK — August 13, 2020 — CB Insights today named Valencell to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. Valencell was named to the list for its scalable biometric sensor systems at the heart of the convergence of consumer wearables and health & medical devices.
The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Other companies named to the list include Bright Health, Biointellisense, Hims & Hers, Omada Health, Oura, Pear Therapeutics, and Virta Health.
“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said CB Insights CEO Anand Sanwal. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year’s class of the best in digital health.”
“Valencell is honored to be named to the Digital Health 150 among the world’s leading companies making incredible advancements in digital health,” said Kent Novak, Valencell CEO. “This recognition is a tribute to the hard work, dedication and innovation of the Valencell team, as well as the groundbreaking collaborations with our customers and partners.”
Valencell’s biometric technology is biosensors for wearable health & medical devices and algorithms for advanced biometrics such as motion-tolerant heart rate, heart rate variability, respiration rate, and cardiac efficiency, among others. As the convergence of consumer wearables and health/medical devices has accelerated, Valencell advanced its technology beyond simple heart rate monitors to provide deeper insights into an individual’s physiological and blood flow characteristics. For example, in January 2020 Valencell launched the world’s first blood pressure monitoring technology that provides BP cuff-level performance without the cuff and does not require calibration for hearables (ear-based devices like earbuds and hearing aids).
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.
Quick facts on the 2020 Digital Health 150:
- The 2020 Digital Health 150 startups have raised over $20B in funding across 600+ deals from 900+ unique investors.
- The list includes 12 unicorns (companies that have reached a valuation of $1B+) focused on a diverse range of digital health solutions, including telehealth, insurance, and robotic surgical systems.
- Many have formed partnerships with key industry players like the American Heart Association, Cigna, and Mount Sinai Health System.
About CB Insights
At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.
CB Insights Contact
Keith Swiader, Manager – PR & Communications
Valencell transforms the science of wearable biometrics to enable impactful health outcomes. Through innovative R&D and validated technologies, we develop breakthroughs and collaborate with wearables, hearables, and medical device companies around the world to deliver amazing results. Protected by more than 100 granted patents and more than 100 patents pending, Valencell’s technology can be used in wearables and hearables for virtually anyone, anywhere, doing anything. Valencell’s biometric sensor systems are currently integrated into more wearable devices than any other technology provider in the world.
VP Marketing at Valencell
Kraudel (at) valencell (dot) com